NSE மற்றும் BSE-யின் ஒவ்வொரு கார்ப்பரேட் அறிவிப்பும், AI-யால் சில நிமிடங்களில் படிக்கப்பட்டு விளக்கப்படுகிறது — தாக்கம், முக்கிய புள்ளிவிவரங்கள், குறுகிய/நீண்டகாலப் பார்வை, கவனிக்க வேண்டியவை.
நேரலைசமீபத்திய அறிவிப்பு: 2026-10-01 17:57இன்று 0 பகுப்பாய்வு செய்யப்பட்டது
குறிப்பு: இவை NSE பொது அறிக்கைகளின் AI-உருவாக்கிய, கல்வி நோக்கச் சுருக்கங்கள் — ஒவ்வொரு ஆவணத்தையும் ஆதாரமாகக் கொண்டவை, ஆனால் முதலீட்டு ஆலோசனை அல்ல, மேலும் முழுமையற்றதாகவும் இருக்கலாம். அசல் அறிக்கையுடன் சரிபார்க்கவும், செயல்படுவதற்கு முன் SEBI-பதிவு பெற்ற முதலீட்டு ஆலோசகரை அணுகவும்.
Viyash Completes 100% Acquisition of Italy's BioForLife for EUR 16.98M Consideration
Viyash Scientific Limited, through its step-down subsidiary Alivira Animal Health Limited (Ireland), has completed the 100% acquisition of Milan-based BioForLife Italia S.r.l. on October 1, 2026. The upfront base consideration stands at EUR 15.0 million plus the agreed reference net financial position as of June 30, 2026. A deferred consideration of EUR 1.976 million remains payable subject to final net financial position adjustments. Total consideration stands at approximately EUR 16.98 million, integrating the Italian animal health entity into Viyash's global business.
உச்சம் நம்பிக்கை
என்ன மாறியதுViyash Scientific's step-down subsidiary consummated the acquisition of 100% equity in BioForLife Italia S.r.l., making it a step-down wholly owned subsidiary.
ஏன் இது முக்கியம்Expands Viyash's animal health footprint into the European market, adding specialized product offerings to its consolidated revenue base.
Base consideration paid: EUR 15.0 millionDeferred consideration: EUR 1.976 millionEquity acquired: 100%Closing date: அக்டோபர் 1, 2026
📅 குறுகிய காலம்Market sentiment should view the completed closing positively following earlier deal disclosures, with attention shifting to integration costs.
📈 நீண்ட காலம்Strengthens global commercial presence in European animal health formulations and offers cross-selling opportunities across Alivira's distribution network.
⚠ அபாய எச்சரிக்கைகள்
Integration risks in overseas subsidiary management
Currency volatility between Euro and INR
👀 கவனிக்க வேண்டியவை
Track the upcoming quarterly results for BioForLife's revenue consolidation and operating margin contribution to Viyash's animal health portfolio.
Viyash Scientific Gets Italian FDI Approval for BioForLife Acquisition; Closing in 2 Months
Viyash Scientific Limited announced that its step-down wholly owned subsidiary, Alivira Animal Health Limited (Ireland), has received Italian FDI/Golden Power regulatory approval for acquiring 100% of BioForLife Italia S.r.l. Following this clearance, the transaction timeline has been revised to complete within two months from September 08, 2026. All other material terms from previous disclosures dated June 8 and July 21, 2026 remain unchanged, though deal value was not disclosed in this filing. The company generated TTM revenue of ₹1,854 crore and net profit of ₹121 crore.
உச்சம் நம்பிக்கை
என்ன மாறியதுObtained key regulatory clearance (Italian FDI/Golden Power) and shifted expected closing date to within two months.
ஏன் இது முக்கியம்Clears a major foreign regulatory hurdle for the 100% buyout, expanding Viyash's animal health footprint in Europe through Alivira.
Acquisition stake: 100%Expected timeline to close: within two months from September 08, 2026Deal consideration: வெளியிடப்படவில்லைTTM வருவாய்: ₹1854 கோடி
📅 குறுகிய காலம்Positive progress removing regulatory overhang on European expansion; price impact likely muted until transaction financials are disclosed.
📈 நீண்ட காலம்Enhances Alivira's European market presence in animal health once fully consolidated into Viyash's operations.
⚠ அபாய எச்சரிக்கைகள்
Customary closing formalities still pending
Acquisition consideration and target financials not disclosed in this filing
👀 கவனிக்க வேண்டியவை
Track the formal completion intimation expected by early November 2026 and watch for financial disclosures detailing the acquisition consideration and target revenue contribution.
Q1 FY27 Revenue rises 20% to ₹946 Cr; Net Profit jumps 115% to ₹79 Cr
Viyash Scientific reported strong Q1 FY27 performance following the completion of its integration, with revenue increasing 19.5% YoY to ₹946 crore. EBITDA surged 59.2% YoY to ₹205 crore as EBITDA margins expanded by ~530 bps to 21.6%. Net profit more than doubled, rising 115% YoY to ₹79 crore, absorbing an incremental ESOP cost of ₹19 crore. The balance sheet strengthened significantly with net debt falling to ₹86 crore (Net Debt/EBITDA of 0.1x).
உச்சம் நம்பிக்கை
என்ன மாறியதுSubmission of the detailed Q1 FY27 earnings call transcript following post-merger integration and strong quarterly operational execution.
ஏன் இது முக்கியம்Demonstrates post-merger integration success, margin expansion, substantial deleveraging to near net debt-free status, and inorganic expansion into European companion animal healthcare.
📅 குறுகிய காலம்Market sentiment should be supported by strong operational results, lower finance costs (₹12.5 cr vs ₹20.4 cr YoY), and healthy US human formulation momentum (+60%).
📈 நீண்ட காலம்With net debt down to 0.1x EBITDA, the company has balance sheet headroom for organic capex in high-potent APIs and CDMO, alongside companion animal expansion in Europe.
⚠ அபாய எச்சரிக்கைகள்
API revenue timing sensitivity and raw material volatility.
Execution and closing conditions for the cross-border European acquisition (Bio For Life).
👀 கவனிக்க வேண்டியவை
Track the closing and integration timeline of the Bio For Life (Italy) acquisition and observe if the 20-22% EBITDA margin trajectory sustains in upcoming quarters.
Viyash Q1 FY27 Revenue up 19.5% to ₹946.4 Cr; EBITDA Margins Expand to 21.6%
Viyash Scientific reported a robust Q1 FY27 with consolidated revenue of ₹946.4 Cr, a 19.5% YoY increase. Profitability saw a significant boost as EBITDA grew 59.2% YoY to ₹204.7 Cr, driven by a 530 bps margin expansion to 21.6%. The company is also expanding its European footprint through the acquisition of Bio For Life in Italy, targeting the companion animal market. Financial health remains strong with Net Debt to EBITDA at a minimal 0.1x.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company has demonstrated significant operational leverage, resulting in a sharp increase in EBITDA margins and a strategic pivot toward the Italian companion animal market via a new acquisition.
ஏன் இது முக்கியம்The successful integration of previous acquisitions is now yielding higher profitability and a cleaner balance sheet, providing the financial flexibility to pursue further inorganic growth in specialized segments.
📅 குறுகிய காலம்The stock is likely to react positively to the strong margin expansion and the double-digit revenue growth in the formulations segment.
📈 நீண்ட காலம்The shift towards specialized animal healthcare and complex APIs, combined with a disciplined M&A approach and low leverage, positions the company for structural margin improvement over the coming years.
⚠ அபாய எச்சரிக்கைகள்
ESOP costs (₹24.6 Cr in Q1) impacting reported PAT
Integration risks associated with the Italian acquisition
👀 கவனிக்க வேண்டியவை
Watch for the completion of the Bio For Life acquisition by September 2026 and the subsequent integration of its 85-90 product companion animal portfolio into the global pipeline.
Viyash to Convert Rs 400 Cr Loan to Equity in Subsidiary; Expands to Vietnam
Viyash Scientific has approved the conversion of a Rs 400.02 Cr intercompany loan into equity for its wholly-owned subsidiary, Alivira Animal Health Limited (AAHL), to strengthen its capital structure and reduce interest costs. The company is also expanding internationally by incorporating a subsidiary in Vietnam with an initial investment of up to USD 400,000. Additionally, the board approved the allotment of 10,30,775 equity shares under its 2026 ESOP scheme at an exercise price of Rs 101 per share. AAHL remains a critical driver for the company, reporting a FY26 turnover of Rs 449.45 Cr, which is approximately 46% of the group's TTM revenue.
உச்சம் நம்பிக்கை
என்ன மாறியதுViyash is restructuring the balance sheet of its primary subsidiary by converting debt to equity and initiating a direct presence in the Vietnamese animal health market.
ஏன் இது முக்கியம்The loan conversion strengthens the financial health of AAHL, which contributes nearly half of the group's revenue. The Vietnam expansion signals a strategic move to capture growth in the Southeast Asian veterinary market.
📅 குறுகிய காலம்The market is likely to view the balance sheet strengthening of the core subsidiary and the international expansion plans positively over the coming weeks.
📈 நீண்ட காலம்The reduction in interest burden at the subsidiary level and the establishment of a distribution network in Vietnam could provide structural support to consolidated profitability.
⚠ அபாய எச்சரிக்கைகள்
Execution risk in the new Vietnam market
Minor equity dilution from ESOP allotments
👀 கவனிக்க வேண்டியவை
Investors should monitor the impact of the loan conversion on AAHL's interest expenses and consolidated margins in upcoming quarters, alongside the execution of the Vietnam market entry.
📊 கடந்த 7 நாட்கள் — உணர்வு அடிப்படையில் பகுப்பாய்வு செய்யப்பட்ட அறிவிப்புகள்
EUR 16.976 Million M&A: Viyash Executes SPA to Acquire BioForLife Italia
Viyash Scientific Limited, through its Irish subsidiary Alivira Animal Health, has executed a definitive Sale and Purchase Agreement (SPA) to acquire 100% of BioForLife Italia s.r.l. for EUR 16.976 million. The deal structure includes an upfront payment of EUR 15.0 million and a deferred consideration of EUR 1.976 million linked to contractual conditions. At current exchange rates, the deal value is approximately Rs 154 crore, representing roughly 15.8% of the company's TTM revenue of Rs 976 crore. The transaction is now pending Italian FDI (Golden Power) clearance.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe acquisition of BioForLife Italia has progressed from a proposal (announced June 8, 2026) to a binding Sale and Purchase Agreement with finalized payment terms.
ஏன் இது முக்கியம்This acquisition significantly expands Viyash's animal health footprint in Europe via its subsidiary Alivira, contributing to inorganic revenue growth and potentially higher-margin specialty generic exposure.
Total Consideration: EUR 16.976 millionUpfront Payment: EUR 15.0 millionDeferred Consideration: EUR 1.976 millionDeal Value vs TTM Revenue: ~15.8%Target Stake: 100%
📅 குறுகிய காலம்The execution of the definitive agreement is a positive milestone that provides clarity on deal terms and valuation, likely supporting stock sentiment.
📈 நீண்ட காலம்If successfully integrated, this acquisition strengthens the company's global animal health portfolio, though the high P/E of 297.9 indicates the market has already priced in significant growth.
⚠ அபாய எச்சரிக்கைகள்
Regulatory risk regarding Italian Golden Power clearance
Integration risk of an international entity
Achievement of contractual conditions for deferred payment
👀 கவனிக்க வேண்டியவை
Investors should monitor the timeline for Italian regulatory approvals and subsequent quarterly results to assess the margin contribution from this European animal health asset.
Viyash Scientific Projects FY26 EBITDA to Reach INR 7,025 MN Following Strategic Merger
Viyash Scientific (formerly Sequent Scientific) outlined its post-merger trajectory, projecting a significant EBITDA increase from INR 2,739 MN in FY24 to INR 7,025 MN by FY26. The company has successfully integrated 16 global manufacturing facilities and an R&D team of over 200 scientists, filing 185+ patents to date. The business model is now diversified across Animal Formulations (45%), API/CDMO (43%), and Human Formulations (12%), leveraging 9 USFDA-approved sites to capture global market trends.
முக்கிய அம்சங்கள்
Projected FY26 revenue of INR 34,203 MN, representing steady growth from INR 26,807 MN in FY24.EBITDA margins are expected to more than double from FY24 levels, reaching INR 7,025 MN in FY26 due to merger synergies.Global footprint established with 16 manufacturing sites across India, USA, Spain, Turkey, and Brazil.Strong R&D pipeline with 60 patents filed since FY23 and 185+ cumulative patents filed.Q4FY26 demonstrated strong momentum with 19% YoY revenue growth and 64% YoY EBITDA growth.
👀 கவனிக்க வேண்டியவை
Investors should focus on the company's execution of its FY26 margin expansion targets and the scaling of its high-margin companion animal and oncology portfolios. The successful integration of Sequent and Viyash assets suggests a strong platform for long-term value creation in the specialized pharma space.
Viyash Scientific to Acquire Italy's BioForLife for ~₹188 Crore to Boost Pet Care Business
Viyash Scientific, through its subsidiary Alivira Animal Health, has signed a binding agreement to acquire a 100% stake in Milan-based BioForLife (BFL) for approximately ₹188 crore. BFL is a prominent Italian pet care company specializing in nutritional complements, pharmaceuticals, and diagnostics, with a distribution network reaching over 80% of veterinary clinics in Italy. The acquisition is expected to close in Q2 FY27 and marks a strategic entry into one of Europe's top five animal health markets. This move aims to capitalize on the high-growth companion animal segment by leveraging BFL's front-end sales team to launch Alivira's product pipeline.
முக்கிய அம்சங்கள்
Acquisition of 100% stake in BioForLife Italia S.r.l. for a cash consideration of ~₹188 crore.Strategic entry into Italy, one of the five largest animal health markets in Europe.BioForLife provides access to over 80% of veterinary clinics in Italy through its established sales team.The transaction is expected to conclude by Q2 FY27, strengthening the global companion animal health portfolio.Synergies include launching Alivira’s pipeline in Italy and expanding BFL’s range to other global markets.
👀 கவனிக்க வேண்டியவை
Investors should view this as a positive strategic expansion into the high-margin companion animal segment; monitor the successful integration and revenue synergies starting from late 2026.
Viyash Scientific to acquire Italy's BioForLife for EUR 16.975 Million
Viyash Scientific's step-down subsidiary, Alivira Animal Health Limited, has entered into a binding agreement to acquire 100% of BioForLife Italia s.r.l. for a total consideration of EUR 16.975 million. BioForLife is a Milan-based distributor of veterinary products for companion animals, reporting a steady revenue increase from EUR 7.1 million in 2023 to EUR 9.0 million in 2025. The acquisition will be funded via cash, with EUR 15.0 million payable at closing and the remainder as deferred consideration, aiming to scale Viyash's presence in the European animal health market.
முக்கிய அம்சங்கள்
Acquisition of 100% stake in BioForLife Italia s.r.l. for an aggregate value of EUR 16.975 million.Target company revenue showed consistent growth: EUR 7.1m (2023), EUR 8.3m (2024), and EUR 9.0m (2025).Payment structure includes EUR 15.0 million upfront and EUR 1.975 million as deferred consideration within 12 months.Strategic move to strengthen the companion animal segment in Italy through an established front-end platform.Transaction is expected to close within 3 months, subject to Italian Golden Power Law approvals.
👀 கவனிக்க வேண்டியவை
Investors should monitor the successful integration of this acquisition as it provides a direct front-end presence in the European companion animal market at a reasonable valuation of approximately 1.88x sales.
Viyash Scientific Proposes ₹4 Crore Incentive for CEO and New Board Appointments
Viyash Scientific Limited has issued a postal ballot notice seeking shareholder approval for key leadership and compensation changes. The company proposes a one-time performance incentive of ₹4,00,00,000 (₹4 Crores) for Mr. Rajaram Narayanan, the Whole-time Director & CEO of Animal Health, to be paid in FY 2026-27. Additionally, the company is seeking the appointment of Mr. Amit Jain and Mr. Abhiroop Jayanthi as Non-Executive, Non-Independent Directors. Shareholders can cast their votes via remote e-voting between May 30 and June 28, 2026.
முக்கிய அம்சங்கள்
Proposed one-time performance incentive of ₹4,00,00,000 for Mr. Rajaram Narayanan, CEO - Animal Health.Appointment of Mr. Amit Jain and Mr. Abhiroop Jayanthi as Non-Executive, Non-Independent Directors.Remote e-voting period set from May 30, 2026, to June 28, 2026, with results by June 30, 2026.The incentive payment is scheduled for the financial year ending March 31, 2027.The resolutions follow previous approvals from the 40th AGM and a March 2026 postal ballot.
👀 கவனிக்க வேண்டியவை
Investors should assess whether the ₹4 crore performance incentive is justified by the company's recent financial trajectory and the CEO's specific contributions. Monitor the voting results on June 30 to gauge institutional and minority shareholder sentiment regarding executive compensation.
Viyash Scientific Reports Strong FY26 Results with PAT Surging 1,324% to ₹225 Crores
Viyash Scientific Limited (formerly Sequent Scientific) reported a transformative FY26, with annual revenue growing 13.8% to ₹3,420 crores and PAT skyrocketing by 1,324% to ₹225 crores. Q4 FY26 was the strongest quarter in the company's history, with EBITDA surpassing ₹200 crores and margins expanding to 21.7%. The company successfully integrated its operations post-merger, leading to significant operational leverage and a credit rating upgrade to AA-. Management is now focusing on high-margin CDMO opportunities and complex product pipelines for FY27.
முக்கிய அம்சங்கள்
FY26 PAT increased by 1,324% to ₹225 crores compared to ₹16 crores in FY25Q4 FY26 EBITDA rose 64% YoY to ₹200 crores with a margin of 21.7%Total FY26 revenue reached ₹3,420 crores, driven by an 18% growth in the formulations segmentExternal credit rating upgraded to AA- (long-term) and A1+ (short-term) reflecting a deleveraged balance sheetAnimal health API business achieved a ₹400 crore run rate after five years of stagnation
👀 கவனிக்க வேண்டியவை
Investors should view this as a successful turnaround story post-merger, with improving margins and a strong pipeline in CDMO and complex generics. Monitor the execution of inorganic growth plans and the ramp-up of the innovator business in FY27.
Viyash Scientific Q4 EBITDA Surges 64% to ₹2,001 Mn; Net Debt/EBITDA Drops to 0.2x
Viyash Scientific reported its strongest quarter ever in Q4 FY26, with revenue growing 19.1% YoY to ₹9,200 million. The company's EBITDA for the quarter jumped 63.8% to ₹2,001 million, driven by merger synergies and improved operating leverage following its integration. For the full year FY26, revenue reached ₹34,203 million with a significant margin expansion of 590 bps to 20.5%. Crucially, the company significantly deleveraged its balance sheet, reducing net debt from ₹4,511 million in FY25 to ₹1,661 million in FY26.
முக்கிய அம்சங்கள்
Q4 FY26 revenue grew 19.1% YoY to ₹9,200 Mn, while full-year FY26 revenue rose 13.8% to ₹34,203 Mn.EBITDA margins expanded by 590 bps YoY to 21.7% in Q4 and 20.5% for the full year FY26.Net Debt reduced by approximately 63% to ₹1,661 Mn, bringing the Net Debt to EBITDA ratio down to 0.2x from 1.0x.Formulations segment led growth with an 18% YoY increase in FY26, driven by strong performance in Europe and Emerging Markets.Successful merger integration achieved with 6 intermediates now validated in-house to replace external procurement.
👀 கவனிக்க வேண்டியவை
Investors should note the sharp margin expansion and successful debt reduction as evidence of strong post-merger synergy realization. The company's transition to a nearly debt-free status and its focus on high-margin formulations make it a strong candidate for long-term growth monitoring.
Viyash Scientific Q4 FY26 PAT Surges 306% to ₹664 Mn; FY26 PAT Jumps 1324%
Viyash Scientific reported its strongest quarter ever in Q4 FY26, with revenues growing 19.1% YoY to ₹9,200 million. The company's full-year FY26 performance was exceptional, with PAT skyrocketing by 1324% to ₹2,246 million, driven by merger synergies and operational integration. EBITDA margins improved significantly to 21.7% in Q4 from 15.8% in the previous year. The balance sheet is now highly deleveraged with a Net Debt/EBITDA ratio of just 0.2x, providing room for future inorganic growth.
முக்கிய அம்சங்கள்
Q4 FY26 EBITDA grew 63.8% YoY to ₹2,001 million with margins expanding to 21.7%Full-year FY26 PAT reached ₹2,246 million, a massive 1324% increase from ₹158 million in FY25Annual revenue for FY26 stood at ₹34,203 million, marking a 13.8% growth over the previous fiscalNet Debt to EBITDA ratio significantly improved to 0.2x, indicating a very strong financial positionManagement highlighted successful integration of facilities and is evaluating selective inorganic opportunities
👀 கவனிக்க வேண்டியவை
Investors should view this as a strong turnaround story with significant margin expansion and debt reduction. The stock is likely to react positively to the record-breaking quarterly performance and robust growth outlook.
Viyash Scientific FY26 Net Profit Grows 30% to ₹758.7 Million; No Dividend Declared
Viyash Scientific Limited reported a strong financial performance for FY26, with consolidated net profit rising 30% to ₹758.7 million from ₹584.9 million in the previous year (restated). Annual revenue from operations increased by 5.5% to ₹13,820.6 million. The company successfully completed a major amalgamation of several entities, which is reflected in the restated figures. Despite the profit growth, the board has opted not to recommend a dividend for FY26 to conserve resources for future expansion.
முக்கிய அம்சங்கள்
Full-year FY26 Net Profit reached ₹758.7 million, a 30% increase over the restated FY25 profit of ₹584.9 million.Q4 FY26 revenue stood at ₹3,724.9 million, showing steady growth compared to ₹3,443.2 million in Q4 FY25.The company achieved a significant turnaround in Q4 FY26 with a profit of ₹358.1 million versus a loss of ₹193.7 million in the same quarter last year.Board approved the grant of 1,30,98,000 stock options to employees under the ESOP Scheme 2026.The company successfully integrated multiple entities following the NCLT-sanctioned Composite Scheme of Amalgamation effective December 2025.
👀 கவனிக்க வேண்டியவை
Investors should monitor the efficiency gains from the recent large-scale merger and the company's ability to scale its pharmaceutical operations. The decision to skip dividends indicates a focus on aggressive reinvestment and growth.
Viyash Scientific Credit Rating Upgraded to 'IND AA-' with Stable Outlook
India Ratings and Research (Ind-Ra) has upgraded the long-term credit rating of Viyash Scientific Limited to 'IND AA-' from 'IND A'. Simultaneously, the short-term rating has been upgraded to 'IND A1+' from 'IND A1'. The upgrade applies to the company's bank loan facilities totaling INR 350 million. This rating action reflects an improvement in the company's credit profile and financial stability, with the outlook now set as Stable.
முக்கிய அம்சங்கள்
Long-term bank facility rating upgraded from 'IND A' to 'IND AA-'Short-term rating upgraded from 'IND A1' to 'IND A1+'Outlook revised to 'Stable' from 'Positive' following the multi-notch upgradeRating applies to fund-based working capital limits of INR 350 million with ICICI Bank
👀 கவனிக்க வேண்டியவை
The credit rating upgrade is a positive signal indicating reduced credit risk and the potential for lower borrowing costs. Investors should view this as a validation of the company's strengthening balance sheet and operational stability.
Viyash Scientific Gets Credit Rating Upgrade to [ICRA]AA- (Stable) for ₹185 Cr Facilities
ICRA Limited has assigned a long-term rating of [ICRA]AA- with a Stable outlook to Viyash Scientific Limited's working capital facilities totaling ₹185.00 Crores. This new rating marks a significant improvement from the company's previous long-term rating of IND A assigned by India Ratings in January 2025. The upgrade reflects a strengthened credit profile and improved financial stability for the pharmaceutical entity. A higher credit rating typically allows a company to access capital at more competitive interest rates, potentially reducing future finance costs.
முக்கிய அம்சங்கள்
ICRA assigned a new long-term rating of [ICRA]AA- (Stable) for ₹185.00 Crores in fund-based facilities.The assigned rating is higher than the previous long-term rating of IND A/Positive issued in early 2025.The rated facilities include ₹150.00 Crores from Kotak Mahindra Bank and ₹35.00 Crores from ICICI Bank.The 'Stable' outlook indicates ICRA's expectation of steady performance and credit metrics in the medium term.
👀 கவனிக்க வேண்டியவை
Investors should take this as a positive indicator of the company's improving financial health and reduced default risk. This upgrade may lead to lower borrowing costs, which could positively impact the company's bottom line over time.
Viyash Scientific Appoints Carlyle Group Nominees to Board and Revises ESOP 2026 Pool
Viyash Scientific Limited has appointed Amit Jain and Abhiroop Jayanthi, both senior leaders from the Carlyle Group, as Non-Executive Directors effective April 22, 2026. This move strengthens the board with significant private equity and healthcare sector expertise, as Carlyle is a major stakeholder. Additionally, the company has revised its ESOP 2026 pool downwards to 1,30,98,000 options from the previously proposed 1,34,75,000 options. These changes indicate a strategic alignment with institutional investors and a slight reduction in potential equity dilution from the employee stock scheme.
முக்கிய அம்சங்கள்
Appointment of Amit Jain (Head of Carlyle India) and Abhiroop Jayanthi (MD, Carlyle) as Non-Executive Directors.Revision of the ESOP 2026 pool to 1,30,98,000 stock options from the earlier 1,34,75,000 options.Both new directors bring over 15 years of experience in private equity, healthcare, and life sciences.The appointments are subject to shareholder approval and are effective from April 22, 2026.
👀 கவனிக்க வேண்டியவை
Investors should view the direct board representation by Carlyle Group as a positive signal for governance and strategic growth. Monitor how this leadership change impacts the company's expansion in the life sciences sector.
Viyash Scientific Shareholders Approve MD Appointment and Significant ESOP Grant
Shareholders of Viyash Scientific Limited have approved the appointment of Dr. Haribabu Bodepudi as Managing Director and Group CEO for a two-year term with a 97.32% majority. The company also received approval to grant stock options exceeding 1% of the issued capital to a specific identified employee, supported by 97.31% of votes. Additionally, the appointments of Mr. Rajaram Narayanan and Mr. Srinivas Vasireddy as Whole-time Directors were cleared with over 98% favor. These results ensure management stability and provide tools for key personnel retention following the company's rebranding.
முக்கிய அம்சங்கள்
Dr. Haribabu Bodepudi confirmed as MD & Group CEO for 2 years with 97.32% votes in favorSpecial resolution passed to grant ESOPs exceeding 1% of issued capital to a single employeeMr. Rajaram Narayanan and Mr. Srinivas Vasireddy appointed as Whole-time Directors with 98.83% and 98.64% support respectivelyTotal voting turnout ranged between 74.8% and 79.3% of outstanding shares across different resolutions
👀 கவனிக்க வேண்டியவை
Investors should take confidence in the high level of shareholder support for the new leadership team. Monitor the company's operational performance under the newly confirmed CEO to validate the long-term growth strategy.
Viyash Scientific Proposes New MD & CEO and ESOP Grant Exceeding 1% Capital
Viyash Scientific Limited has issued a postal ballot notice seeking shareholder approval for the appointment of Dr. Haribabu Bodepudi as Managing Director and Group CEO for a two-year term. A key resolution includes the grant of stock options to Dr. Bodepudi exceeding 1% of the company's issued capital within a single year under the ESOP Scheme 2026. The company is also seeking approval for the appointments of Mr. Rajaram Narayanan and Mr. Srinivas Vasireddy as Whole-time Directors. The e-voting process for these special resolutions will conclude on March 12, 2026.
முக்கிய அம்சங்கள்
Appointment of Dr. Haribabu Bodepudi as MD and Group CEO for a 2-year tenure effective Dec 16, 2025Proposal to grant ESOPs exceeding 1% of total issued capital to the CEO in a single yearAppointment of Mr. Rajaram Narayanan and Mr. Srinivas Vasireddy as Whole-time DirectorsRemote e-voting period scheduled from February 11, 2026, to March 12, 2026Results of the postal ballot to be announced on or before March 16, 2026
👀 கவனிக்க வேண்டியவை
Investors should monitor the voting results to see if the significant ESOP grant is approved, as it indicates potential equity dilution. Evaluate the new leadership's ability to drive growth following the company's rebranding from Sequent Scientific.
Viyash Scientific Q3 FY26 Revenue Up 11% to ₹858 Cr; Adjusted EBITDA Surges 64%
Viyash Scientific reported a robust performance for Q3 FY26, with revenue growing 11% YoY to ₹858 crores and adjusted EBITDA rising 64% to ₹185 crores. The company achieved a significant margin expansion of 390 basis points to 21%, driven by vertical integration and operational efficiencies. Despite one-time merger-related exceptional costs of approximately ₹49 crores, the balance sheet strengthened as net debt-to-EBITDA fell below 4x. Management is now pivoting toward high-growth segments like companion animals and CDMO services.
முக்கிய அம்சங்கள்
Revenue for Q3 FY26 stood at ₹858 crores, up 11% YoY, while 9-month revenue reached ₹2,500 crores.Adjusted EBITDA grew 64% YoY to ₹185 crores with a healthy margin of 21%.Net debt-to-EBITDA leverage improved significantly to less than 4x compared to the previous year.Incurred one-time exceptional items of ₹41 crores for merger execution and ₹7.7 crores for tax regime transitions.Signed an exclusive distribution agreement with Boehringer Ingelheim to expand the companion animal business in India.
👀 கவனிக்க வேண்டியவை
Investors should take note of the significant margin improvement and successful debt reduction following the SeQuent-Viyash merger. The stock remains a watch for long-term growth as the company scales its high-margin companion animal and CDMO verticals.
⚠️இந்தத் தளம் எவ்வாறு உருவாக்கப்படுகிறது: சந்தைத் தரவுப் பக்கங்கள் NSE/BSE வெளியீடுகள் மற்றும் நிறுவனங்களின் தாக்கல்களிலிருந்து தானாகக் கணக்கிடப்படுகின்றன; செய்திக் கட்டுரைகளும் அறிவிப்புப் பகுப்பாய்வுகளும் AI உதவியுடன் எழுதப்படுகின்றன, மனித மேற்பார்வையுடன்: AI உருவாக்குவதை எங்கள் ஆசிரியர்கள் மதிப்பாய்வு செய்கின்றனர். இரண்டிலும் பிழைகள் இருக்கலாம். எந்தவொரு முதலீட்டு முடிவுக்கு முன்பும் அசல் மூலங்களில் சரிபார்க்கவும். முதலீட்டு ஆலோசனை அல்ல; Flash Finance SEBI-பதிவு பெற்றது அல்ல. நாங்கள் AI-ஐ எவ்வாறு பயன்படுத்துகிறோம்
🎁 ஆரம்பகால ஆதரவாளர்களுக்கு மட்டும் · குறுகிய கால சலுகை
எங்கள் AI பங்குச் சந்தை பகுப்பாய்வு: டெலிகிராம், வாட்ஸ்அப்பில் இலவசம்
⚡ 3500+ நிறுவனங்களை நாங்கள் உடனுக்குடன் கண்காணிக்கிறோம். NSE-யில் ஒரு நிறுவன அறிவிப்பு வெளியானதுமே, எங்கள் AI அதைப் படித்து, சுருக்கி, அதன் தாக்கத்தைச் சில நொடிகளில் உங்களுக்குச் சொல்கிறது.
இதுபோன்ற AI பகுப்பாய்வுக்குக் கட்டணத் தளங்கள் ஆண்டுக்கு ₹1,00,000-க்கும் மேல் வசூலிக்கின்றன. எங்கள் சேனல்களில் இது இலவசம்.
